Abstract 332P
Background
The COVID19 pandemic has affected the spectrum of cancer care worldwide. EOCRC is defined as diagnosis below the age of 50. Patients (pts) with EOCRC face multiple challenges, while the COVID19 pandemic caused disruptions in cancer diagnosis and care delivery. Our study aims to identify the clinicopathological features (CF) and outcomes of pts with EOCRC in our Centre during the first wave (FW) of the pandemic compared to the same period in 2019 and 2021.
Methods
Consecutive pts with EOCRC visited for the first time at Vall d’Hebron University Hospital in Spain from the 1 March-30 June 2019, 2020 and 2021 were included in the analysis. Data of CF and treatment were collected from medical records. Data were summarized using descriptive statistics. Quantitative and categorical variables were compared using Wilcoxon rank-sum test and Fisher’s exact test.
Results
136 pts with EOCRC were visited for the first time between 2019 and 2021, of which 53% met the inclusion criteria (2019: 19%, 2020: 40%, 2021: 41%). Table summarizes CF and outcomes. Of note, indication of systemic therapy in the adjuvant or metastatic setting was not altered during the FW. No statistical differences (SD) were found when comparing stage at first visit in 2019, 2020 and 2021 (p=0.7). Of 29%, 38% and 40% of pts starting treatment for the first time in our Centre in the given period in 2019, 2020 and 2021 respectively, median (M) days to treatment initiation (TI) was 18.5, 20 and 23. No SD were found when comparing frequency of pts starting treatment (p=0.6) and days to TI (p=0.4) in 2019, 2020 and 2021. 4 (29%), 7 (24%), and 7 (23%) pts were included in clinical trials (CT) in 2019, 2020 and 2021, respectively. No SD were found (p=0.70). Table: 332P
| 2019 | 2020 | 2021 | |
| Age, M (range) | 41 (27-49) | 43 (29-49) | 44.5 (30-49) |
| Female, n (%) | 7 (50%) | 14 (48%) | 15 (50%) |
| Stage at diagnosis (localized/metastatic), % | 36%/64% | 28%/62% | 43%/57% |
| Stage at visit in our Centre (localized/metastatic), % | 22%/78% | 11%/89% | 17%/83% |
| Site of primary tumor (right/left/rectum), % | 28%/44%/28% | 14%/69%/17% | 37%/40%/23% |
| KRAS/NRAS/BRAF/Unknown, % | 64%/7%/7%/7% | 45%/0%/4%/14% | 34%/4%/4%/26% |
| MSI, n (%) | 1, 7% | 2, 7% | 2, 7% |
| Patients starting treatment, n (%) | 4 (28%) | 11 (38%) | 12 (40%) |
| Days to treatment initiation, M (range) | 18.5 (17-23) | 20 (7-76) | 23 (2-69) |
| Inclusion in clinical trials, n (%) | 4 (28%) | 7 (24%) | 7 (23%) |
Conclusions
Our study shows a progressive increase in EOCRC, despite COVID-19 pandemic. Fortunately, no SD in stage of the disease, treatment indication and TI were found during the FW of the pandemic compared to the same period in 2019 and 2021. Rate of inclusion in CT in this subpopulation with unmet clinical needs is relatively high.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
I. Baraibar Argota: Financial Interests, Personal, Invited Speaker: Sanofi. F. Salvà Ballabrera: Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Invited Speaker: Sanofi, Merck, Servier, Roche. F.J. Ros Montana: Financial Interests, Institutional, Invited Speaker: Sanofi; Other, Other, Travel and accommodation expenses: Amgen, Pierre-Fabre, Merck, Sanofi. J. Hernando Cubero: Financial Interests, Personal, Expert Testimony: Eisai, Ipsen, Novartis, AAA, Angelini, Pfizer, Roche. J. Capdevila Castillon: Financial Interests, Personal, Invited Speaker: Novartis, Novartis, Pfizer, Ipsen, Exelixis, Bayer, Eisai, Advanced Accelerator Applications, Amgen, Sanofi, Lilly, Merck Serono; Financial Interests, Personal, Advisory Board: Pfizer, Ipsen, Exelixis, Bayer, Eisai, Advanced Accelerator Applications, Amgen, Sanofi, Lilly, Merck Serono; Financial Interests, Personal, Research Grant: Novartis, Pfizer, AstraZeneca, Advanced Accelerator Applications, Eisai, Bayer. P.G. Nuciforo: Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Advisory Board: MSD Oncology, Bayer; Financial Interests, Personal, Other, Consultant: Targos Molecular Pathology GmbH. A. Vivancos: Financial Interests, Personal, Advisory Board: Roche, Bristol-Myers Squibb, Guardant Health, Bayer, Incyte; Financial Interests, Personal, Stocks/Shares: Reveal Genomics; Financial Interests, Institutional, Research Grant, Preclinical Research Grant: Bristol-Myers Squibb, Roche, Incyte. J. Tabernero: Financial Interests, Personal, Advisory Board, scientific consultancy role: Orion Biotechnology, Array Biopharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai, Daichii Sankyo, F. Hoffmann-La Roche Ltd, Genentech Inc., HalioDX SAS, Ikena Oncology, IQVIA, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, Neophore, Novartis, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Seattle Genetics, Servier, Taiho, Tessa Therapeutics, TheraMyc, Hutchinson MediPharma International, Avvinity, Scandion Oncology, Ona Therapeutics, Sotio Biotech, Inspirna Inc; Financial Interests, Personal, Invited Speaker, educational collaboration: Medscape Education, Physicians Education Resource (PER), PeerView Institute for Medical Education, Imedex; Financial Interests, Personal, Invited Speaker, educacional collaboration: MJH Life Sciences; Financial Interests, Institutional, Research Grant, ACRCelerate: Colorectal Cancer Stratified: Fundación Científica de la Asociación Española Contra el Cáncer; Financial Interests, Institutional, Research Grant, OPTIMISTICC: Opportunity to Investigate the Microbiome’s Impact on Science and Treatment In Colorectal Cancer: Cancer Research UK; Financial Interests, Institutional, Funding, Clinical Trials & Research: Amgen Inc, Array Biopharma Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb International Corporation, Celgene International SARL, Debiopharm International SA, F. Hoffmann-La Roche Ltd, Genentech Inc, Janssen-Cilag International NV, Merck Health KGAA, Merck, Sharp & Dohme de España, SA, Novartis Farmacéutica SA, PharmaMar SA, Sanofi-Aventis Recherche & Développement, Servier, Taiho Pharma USA, Inc, BeiGene, Boehringer Ingelheim, HalioDX SAS, Hutchinson Medipharma, MedImmune, Menarini, Merus N V, Pfizer, Mirati; Non-Financial Interests, Invited Speaker, Board of Directors: Cancer Core Europe, Spanish Association Against Cancer -AECC; Non-Financial Interests, Invited Speaker, General Assembly: Horizon Europe Cancer Mission; Non-Financial Interests, Leadership Role, External Scientific Committee: Institute for Health Research INCLIVA – Clinical Hospital of Valencia, IdiSNA –Universidad de Navarra; Non-Financial Interests, Leadership Role, Scientific Advisory Board: Spanish National Cancer Research Centre (CNIO); Non-Financial Interests, Advisory Role, International Scientific Evaluation Committee: Bosch Health Campus (BHC); Non-Financial Interests, Advisory Role, Review Board: National Decade Against Cancer (NCT) - German Consortium for Translational Cancer Research (DKTK); Non-Financial Interests, Advisory Role, Scientific Advisory Board: Karolinska Comprehensive Cancer Centre; Non-Financial Interests, Advisory Role, International Review Committee (IRC): Oncode Institute; Non-Financial Interests, Advisory Role, Scientific Advisory Board (SAB): Oslo University Hospital Comprehensive Cancer Centre (OUH CCC); Non-Financial Interests, Leadership Role, Governance Advisory Committee: European Organization for Research and Treatment of Cancer - EORTC; Non-Financial Interests, Leadership Role, Vice Chairman: World Innovative Networking (WIN) Consortium in Personalized Cancer Medicine; Non-Financial Interests, Other, Coordinating PI & Steering Committee Member. Clinical Trials & Research: Array Biopharma Inc., AstraZeneca Pharmaceutical LP, Boehringer Ingelheim, MedImmune, Menarini, Merck Healthcare KGAA, Merck, Sharp & Dohme de España SA, Pfizer, Servier; Non-Financial Interests, Principal Investigator, Clinical Trials & Research: Array Biopharma Inc., AstraZeneca Pharmaceutics LP, BeiGene, Boehringer Ingelheim, Bristol-Myers Squibb International Corporation, Celgene International SARL, Debiopharm International SA, F. Hoffmann-La Roche Ltd, Genentech Inc., HalioDX SAS, Hutchinson Medipharma, Janssen-Cilag International NV, MedImmune, Menarini, Merck Healthcare KGAA, Merck, Sharp & Dohme de España SA, Merus NV, Mirati, Novartis Farmacéutica SA, Pfizer, Sanofi-Aventis Recherche & Développement, Servier, Taiho Pharma USA Inc; Non-Financial Interests, Other, Steering Committee Member. Clinical Trials & Research: Debiopharm International SA, F. Hoffmann-La Roche Ltd, Genentech Inc., HalioDX SAS, Hutchinson Medipharma, Janssen-Cilag International NV, Merus NV, Taiho Pharma USA Inc; Non-Financial Interests, Other, Coordinating PI. Clinical Trials & Research: Mirati; Non-Financial Interests, Member: AACR, ASCO, EACR, EORTC, SEOM; Other, Other, President: Oncology Master Plan – Catalonia Department of Health; Other, Other, Advisory Committee: Advisory Committee on Pharmaceutical Provision Financing under the Spanish National Health System. M.E. Elez Fernandez: Financial Interests, Personal, Advisory Board: Hoffman La - Roche, Bristol-Myers Squibb, Servier, Amgen, Merck Serono, Array Biopharma, Sanofi, Bayer; Financial Interests, Institutional, Research Grant: Hoffman La-Roche, Sanofi Aventis, Amgen, Merck Serono, MSD, Boehringer Ingelheim, AbbVie, Pierre-Fabre, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Medimmune, Array Pharmaceuticals, AstraZeneca. All other authors have declared no conflicts of interest.